title: [Transdermal nitroglycerin in patients with stable angina].
abstract: OBJECTIVE
  To evaluate the nitroglycerin patches efficacy and tolerability in patients with stable angina pectoris.
  
  
  METHODS
  One thousand and five hundred and thirty nine patients with stable angina pectoris, mean age 61.0 +/- 10.3, 891 men and 648 women were prospectively evaluated by five hundred and thirty five specialists after 5 mg or, posteriorly, if clinical necessary, 10 mg of nitroglycerin patches during 12 weeks. Clinical evaluation, electrocardiogram (ECG) and treadmill exercise were obtained on study entry and at weeks 2, 4, 8 and 12 for clinical evaluation, and at week 12 for ECG and treadmill exercise.
  
  
  RESULTS
  A significative reduction was observed in the number of angina crisis, sublingual nitrates consumption, arterial blood pressure and on the percentage of positive treadmill exercise tests. The heart rate and nitroglycerin patches dose did not show statistical differences. The compliance of transdermal administration was excellent.
  
  
  CONCLUSIONS
  The nitroglycerin patches administration was effective for stable angina pectoris with excellent patient's compliance.
authors.affiliation: INCOR, São Paulo.
authors.forename: J A
authors.initials: JA
authors.lastname: Ramires
authors.forename: N
authors.initials: N
authors.lastname: Ghorayeb
authors.forename: A P
authors.initials: AP
authors.lastname: Mansur
authors.forename: M
authors.initials: M
authors.lastname: Batlouni
authors.forename: S F
authors.initials: SF
authors.lastname: Oliveira
authors.forename: P L
authors.initials: PL
authors.lastname: da Luz
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage* / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D005996:Nitroglycerin
vernacular_title: Nitroglicerina transdérmica em portadores de angina estável.